Email this article to a friend
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
-
* Corresponding author: Larry Moreland larry.moreland@ccc.uab.edu
Arthritis Res 2001, 3:247-252 doi:10.1186/ar309